Ipca takes control of US player Bayshore
Ipca Laboratories has paid just under US$10.3 million in cash for 80% of the share capital in US generics player Bayshore Pharmaceuticals. The Indian company said that acquiring the majority stake in sales and marketing firm Bayshore through its wholly-owned US subsidiary Ipca Pharmaceuticals would “enable the firm to commercialise its registered generic drug products in the US market through this entity”.
You may also be interested in...
Ipca has struck a deal to take full ownership of US firm Bayshore Pharmaceuticals by acquiring the remaining 20% stake that it did not already own.
India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.